Bradburn M J, Altman D G, Smith P, Fentiman I S, Rubens R D
Imperial Cancer Research Fund Medical Statistics Group, Centre for Statistics in Medicine, Institute of Health Sciences, Oxford, UK.
Br J Cancer. 1998 Jun;77(11):1944-9. doi: 10.1038/bjc.1998.322.
The aim of this retrospective cohort study was to investigate whether survival of patients with breast cancer has changed over the period 1975-89. A total of 2604 women diagnosed as having invasive breast cancer at a clinical oncology unit in London were followed up for between 5 and 20 years. Patients were divided into four groups according to menstrual status (pre or post) and the staging of cancer (operable or inoperable). For each group, survival from diagnosis was compared between three consecutive 5-year cohorts, both with and without adjustments made for relevant prognostic factors. No temporal patterns were found in patients with inoperable cancer, in whom the survival rate was consistently low. Of women with operable cancers, differences were seen only among post-menopausal women, for whom the best survival patterns were seen in patients diagnosed between 1985-89. This is probably due to tamoxifen being commonly prescribed as adjuvant treatment for this cohort of patients. We cannot explain an apparently worse survival in the group of patients presenting in the early 1980s compared with that observed in the late 1970s.
这项回顾性队列研究的目的是调查1975年至1989年期间乳腺癌患者的生存率是否发生了变化。对伦敦一家临床肿瘤科室诊断为浸润性乳腺癌的2604名女性进行了5至20年的随访。患者根据月经状态(绝经前或绝经后)和癌症分期(可手术或不可手术)分为四组。对于每组,在对相关预后因素进行调整和未调整的情况下,比较了三个连续5年队列中从诊断开始的生存率。在不可手术癌症患者中未发现时间模式,其生存率一直较低。在可手术癌症的女性中,仅在绝经后女性中观察到差异,其中1985年至1989年诊断的患者生存率最佳。这可能是由于他莫昔芬通常被用作该组患者的辅助治疗。我们无法解释与20世纪70年代末相比,20世纪80年代初就诊的患者组生存率明显更差的原因。